Keyphrases
Adverse Events
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Radiation Therapy
100%
Treatment Regimen
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Dose-escalation Trial
100%
Hypofractionated Radiation Therapy
100%
Maximum Tolerated Dose
66%
Dose Level
66%
No Significant Difference
33%
Long-term Safety
33%
Clinical Outcomes
33%
Long-term Efficacy
33%
Esophagitis
33%
Dyspnea
33%
Technological Progress
33%
Hypofractionation
33%
Cost-effectiveness
33%
Effective Therapy
33%
Surgical Resection
33%
Concurrent Chemoradiation
33%
Tumoricidal Activity
33%
Median Overall Survival
33%
Lung Cancer Treatment
33%
Conformal Radiation Therapy
33%
Chemoradiation
33%
Poor Performance Status
33%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
33%
Stereotactic Radiation
33%
Fraction Size
33%
Recurrent Non-small Cell Lung Cancer
33%
Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Hypofractionated Radiotherapy
100%
Adverse Event
60%
Radiation Therapy
60%
Chemoradiotherapy
40%
Oncology
20%
Disease
20%
Surgery
20%
Dyspnea
20%
Lung Cancer
20%
Esophagitis
20%
Cost-Effectiveness Analysis
20%
Overall Survival
20%
Cancer Therapy
20%
Conformal Radiotherapy
20%
Spine
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Adverse Event
60%
Chemoradiation Therapy
40%
Maximum Tolerated Dose
40%
Disease
20%
Dyspnea
20%
Lung Cancer
20%
Overall Survival
20%
Esophagitis
20%